Completed PHASE1 INTERVENTIONAL 1-arm NCT02045368

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)

Sponsor: IGF Oncology, LLC

Conditions Brain Cancer Breast Cancer Gastrointestinal Cancers Genitourinary Cancers Gynecologic Cancers Head and Neck Cancers Melanoma Thoracic Cancers

Interventions IGF-Methotrexate conjugate

Updated 8 times since 2017 Last updated: Aug 20, 2019 Started: Jan 28, 2014 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Brain Cancer and Breast Cancer, this trial is completed. The trial is conducted by IGF Oncology, LLC and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2019 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Feb 2017 — Jun 2017 [monthly]

Unknown Status PHASE1
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IGF Oncology, LLC

Data source: IGF Oncology, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States